Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ARIA 2017: a Review of Major Changes and Innovations

ARIA 2017: a Review of Major Changes and Innovations Background Allergic rhinitis is a disease underestimated by patients, and underdiagnosed and thus undertreated by physicians since most of the patients present with symptoms of moderate-to-severe disease, overall diminished quality of life, impairing sleep quality and cognitive function, and a substantial impact on work productivity, school absenteeism, and costs. The relationship between treating physician and patients is crucial in all chronic diseases. Objectives Review the main changes and innovations of recent years in the ARIA guide- lines. Methods The most recent publications of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were reviewed. Results ARIA 2016 strengthens the role of patients in the control and treatment of their symptoms by the use of technology, which improves physician-patient communication. The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. It confirms that inhaled corticosteroids are the most effective drugs for the management of seasonal or perennial allergic rhinitis, not surpassed by combination therapies with oral or topical antihistamines. On the other hand, no significant differences between the use of oral or topical antihistamines are evidenced. Allergen exposure and the resulting symptoms http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Treatment Options in Allergy Springer Journals

ARIA 2017: a Review of Major Changes and Innovations

Loading next page...
 
/lp/springer_journal/aria-2017-a-review-of-major-changes-and-innovations-wByZvfQOAf
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Allergology; General Practice / Family Medicine
eISSN
2196-3053
DOI
10.1007/s40521-018-0166-4
Publisher site
See Article on Publisher Site

Abstract

Background Allergic rhinitis is a disease underestimated by patients, and underdiagnosed and thus undertreated by physicians since most of the patients present with symptoms of moderate-to-severe disease, overall diminished quality of life, impairing sleep quality and cognitive function, and a substantial impact on work productivity, school absenteeism, and costs. The relationship between treating physician and patients is crucial in all chronic diseases. Objectives Review the main changes and innovations of recent years in the ARIA guide- lines. Methods The most recent publications of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were reviewed. Results ARIA 2016 strengthens the role of patients in the control and treatment of their symptoms by the use of technology, which improves physician-patient communication. The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. It confirms that inhaled corticosteroids are the most effective drugs for the management of seasonal or perennial allergic rhinitis, not surpassed by combination therapies with oral or topical antihistamines. On the other hand, no significant differences between the use of oral or topical antihistamines are evidenced. Allergen exposure and the resulting symptoms

Journal

Current Treatment Options in AllergySpringer Journals

Published: May 16, 2018

References